血清脑源性神经营养因子(BDNF)、神经元特异性烯醇化酶(NSE)、胶质纤维酸性蛋白(GFAP)、血浆粘度(PV)、纤维蛋白原(FIB)对急性脑梗死患者的诊断价值。

IF 1.5 4区 医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY
Tinghuan Wang, Fei Wang, Xinglu Dong, Xiaofeng Liu, Zhiyu Cui, Yingshuai Shi
{"title":"血清脑源性神经营养因子(BDNF)、神经元特异性烯醇化酶(NSE)、胶质纤维酸性蛋白(GFAP)、血浆粘度(PV)、纤维蛋白原(FIB)对急性脑梗死患者的诊断价值。","authors":"Tinghuan Wang, Fei Wang, Xinglu Dong, Xiaofeng Liu, Zhiyu Cui, Yingshuai Shi","doi":"10.5937/jomb0-55111","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To explore the Diagnostic value of serum brain-derived neurotrophic factor (BDNF), neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), plasma viscosity (PV) as well as fibrinogen (FIB) in patients receiving butylphthalide and sodium chloride injection in combination with atorvastatin calcium in acute cerebral infarction patients.</p><p><strong>Methods: </strong>Eighty ACI patients treated at our hospital between January 2022 and January 2024 were included as study participants, followed by divided into the control group (CG) and study group (SG). The CG was given atorvastatin calcium tablets. Based on the CG, the SG received a butylphthalide sodium chloride injection. The clinical efficacy, neurological impairment, daily living ability, hemorheological indicators, neurobiochemical indicators, and occurrence of adverse reactions in the two groups were compared.</p><p><strong>Results: </strong>Compared to the CG, the SG's total effective clinical effect rate was significantly higher (P<0.05). After therapy, the NIHSS score in the SG showed a significant reduction relative to the CG, and the BI score in the SG was significantly higher relative to the CG (P<0.05). The whole blood high shear viscosity, whole blood low shear viscosity, PV, HCT, and FIB levels in the SG, were significantly reduced relative to the CG (P< 0.05). The improvements of BDNF NSE, and GFAP levels in the SG were significantly superior to the CG (P< 0.05). No significant differences in adverse reactions were observed between the two groups (P>0.05).</p><p><strong>Conclusions: </strong>The combination of butylphthalide sodium chloride injection and atorvastatin calcium tablets significantly improved clinical outcomes in ACI patients by improving neurological function, daily living ability, cerebral hemodynamics, and neurobiochemical markers. This therapeutic regimen offers a promising approach to ACI management and warrants further clinical promotion. The novel aspect of this study lies in its comprehensive evaluation of both neurological and hemodynamic improvements, highlighting the potential synergistic benefits of this combined therapy.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 5","pages":"1092-1099"},"PeriodicalIF":1.5000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433302/pdf/","citationCount":"0","resultStr":"{\"title\":\"Diagnostic value of serum brain-derived neurotrophic factor (BDNF), neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), plasma viscosity (PV) as well as fibrinogen (FIB) in acute cerebral infarction patients.\",\"authors\":\"Tinghuan Wang, Fei Wang, Xinglu Dong, Xiaofeng Liu, Zhiyu Cui, Yingshuai Shi\",\"doi\":\"10.5937/jomb0-55111\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>To explore the Diagnostic value of serum brain-derived neurotrophic factor (BDNF), neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), plasma viscosity (PV) as well as fibrinogen (FIB) in patients receiving butylphthalide and sodium chloride injection in combination with atorvastatin calcium in acute cerebral infarction patients.</p><p><strong>Methods: </strong>Eighty ACI patients treated at our hospital between January 2022 and January 2024 were included as study participants, followed by divided into the control group (CG) and study group (SG). The CG was given atorvastatin calcium tablets. Based on the CG, the SG received a butylphthalide sodium chloride injection. The clinical efficacy, neurological impairment, daily living ability, hemorheological indicators, neurobiochemical indicators, and occurrence of adverse reactions in the two groups were compared.</p><p><strong>Results: </strong>Compared to the CG, the SG's total effective clinical effect rate was significantly higher (P<0.05). After therapy, the NIHSS score in the SG showed a significant reduction relative to the CG, and the BI score in the SG was significantly higher relative to the CG (P<0.05). The whole blood high shear viscosity, whole blood low shear viscosity, PV, HCT, and FIB levels in the SG, were significantly reduced relative to the CG (P< 0.05). The improvements of BDNF NSE, and GFAP levels in the SG were significantly superior to the CG (P< 0.05). No significant differences in adverse reactions were observed between the two groups (P>0.05).</p><p><strong>Conclusions: </strong>The combination of butylphthalide sodium chloride injection and atorvastatin calcium tablets significantly improved clinical outcomes in ACI patients by improving neurological function, daily living ability, cerebral hemodynamics, and neurobiochemical markers. This therapeutic regimen offers a promising approach to ACI management and warrants further clinical promotion. The novel aspect of this study lies in its comprehensive evaluation of both neurological and hemodynamic improvements, highlighting the potential synergistic benefits of this combined therapy.</p>\",\"PeriodicalId\":16175,\"journal\":{\"name\":\"Journal of Medical Biochemistry\",\"volume\":\"44 5\",\"pages\":\"1092-1099\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-08-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433302/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medical Biochemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5937/jomb0-55111\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5937/jomb0-55111","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:探讨血清脑源性神经营养因子(BDNF)、神经元特异性烯醇化酶(NSE)、胶质纤维酸性蛋白(GFAP)、血浆黏度(PV)和纤维蛋白原(FIB)在急性脑梗死患者服用丁苯酞氯化钠注射液联合阿托伐他汀钙治疗中的诊断价值。方法:选取2022年1月~ 2024年1月在我院收治的80例ACI患者作为研究对象,分为对照组(CG)和研究组(SG)。对照组给予阿托伐他汀钙片。在CG的基础上,SG接受了丁苯酞氯化钠注射。比较两组患者的临床疗效、神经功能损害、日常生活能力、血液流变学指标、神经生化指标及不良反应发生情况。结果:SG组临床总有效率明显高于CG组(P0.05)。结论:丁苯酞氯化钠注射液联合阿托伐他汀钙片可改善ACI患者的神经功能、日常生活能力、脑血流动力学及神经生化指标,显著改善ACI患者的临床预后。这种治疗方案为ACI的治疗提供了有希望的方法,值得进一步的临床推广。这项研究的新颖之处在于它对神经学和血流动力学的改善进行了综合评估,强调了这种联合治疗的潜在协同效益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Diagnostic value of serum brain-derived neurotrophic factor (BDNF), neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), plasma viscosity (PV) as well as fibrinogen (FIB) in acute cerebral infarction patients.

Diagnostic value of serum brain-derived neurotrophic factor (BDNF), neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), plasma viscosity (PV) as well as fibrinogen (FIB) in acute cerebral infarction patients.

Diagnostic value of serum brain-derived neurotrophic factor (BDNF), neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), plasma viscosity (PV) as well as fibrinogen (FIB) in acute cerebral infarction patients.

Diagnostic value of serum brain-derived neurotrophic factor (BDNF), neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), plasma viscosity (PV) as well as fibrinogen (FIB) in acute cerebral infarction patients.

Background: To explore the Diagnostic value of serum brain-derived neurotrophic factor (BDNF), neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), plasma viscosity (PV) as well as fibrinogen (FIB) in patients receiving butylphthalide and sodium chloride injection in combination with atorvastatin calcium in acute cerebral infarction patients.

Methods: Eighty ACI patients treated at our hospital between January 2022 and January 2024 were included as study participants, followed by divided into the control group (CG) and study group (SG). The CG was given atorvastatin calcium tablets. Based on the CG, the SG received a butylphthalide sodium chloride injection. The clinical efficacy, neurological impairment, daily living ability, hemorheological indicators, neurobiochemical indicators, and occurrence of adverse reactions in the two groups were compared.

Results: Compared to the CG, the SG's total effective clinical effect rate was significantly higher (P<0.05). After therapy, the NIHSS score in the SG showed a significant reduction relative to the CG, and the BI score in the SG was significantly higher relative to the CG (P<0.05). The whole blood high shear viscosity, whole blood low shear viscosity, PV, HCT, and FIB levels in the SG, were significantly reduced relative to the CG (P< 0.05). The improvements of BDNF NSE, and GFAP levels in the SG were significantly superior to the CG (P< 0.05). No significant differences in adverse reactions were observed between the two groups (P>0.05).

Conclusions: The combination of butylphthalide sodium chloride injection and atorvastatin calcium tablets significantly improved clinical outcomes in ACI patients by improving neurological function, daily living ability, cerebral hemodynamics, and neurobiochemical markers. This therapeutic regimen offers a promising approach to ACI management and warrants further clinical promotion. The novel aspect of this study lies in its comprehensive evaluation of both neurological and hemodynamic improvements, highlighting the potential synergistic benefits of this combined therapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Medical Biochemistry
Journal of Medical Biochemistry BIOCHEMISTRY & MOLECULAR BIOLOGY-
CiteScore
3.00
自引率
12.00%
发文量
60
审稿时长
>12 weeks
期刊介绍: The JOURNAL OF MEDICAL BIOCHEMISTRY (J MED BIOCHEM) is the official journal of the Society of Medical Biochemists of Serbia with international peer-review. Papers are independently reviewed by at least two reviewers selected by the Editors as Blind Peer Reviews. The Journal of Medical Biochemistry is published quarterly. The Journal publishes original scientific and specialized articles on all aspects of clinical and medical biochemistry, molecular medicine, clinical hematology and coagulation, clinical immunology and autoimmunity, clinical microbiology, virology, clinical genomics and molecular biology, genetic epidemiology, drug measurement, evaluation of diagnostic markers, new reagents and laboratory equipment, reference materials and methods, reference values, laboratory organization, automation, quality control, clinical metrology, all related scientific disciplines where chemistry, biochemistry, molecular biology and immunochemistry deal with the study of normal and pathologic processes in human beings.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信